T1	p 65 88	severe bronchiectasis .
T2	p 233 242	infective
T3	p 251 270	in bronchiectasis .
T4	p 416 489	bronchiectasis . Twenty-four patients ( 12 female ; mean age 51 yr ) were
T5	p 1469 1485	bronchiectasis .
T6	i 14 25	fluticasone
T7	i 98 120	corticosteroid therapy
T8	i 316 334	placebo-controlled
T9	i 393 412	inhaled fluticasone
T10	i 523 558	inhaled fluticasone ( 500 microgram
T11	i 565 599	daily ) via the Accuhaler device (
T12	i 604 621	12 ) or placebo .
T13	i 826 837	leukotriene
T14	i 979 990	fluticasone
T15	i 1007 1018	fluticasone
T16	i 1041 1048	placebo
T17	i 1247 1258	fluticasone
T18	i 1411 1434	inhaled steroid therapy
T19	o 34 61	sputum inflammatory indices
T20	o 638 648	spirometry
T21	o 651 849	24-h sputum volume , sputum leukocyte density , bacterial densities , and concentrations of interleukin ( IL ) -1beta , IL-8 , tumor necrosis factor-alpha ( TNF-alpha ) , and leukotriene B4 ( LTB4 )
T22	o 914 961	in sputum leukocyte density and IL-1beta , IL-8
T23	o 1125 1135	spirometry
T24	o 1165 1182	adverse reactions
T25	o 1284 1347	the sputum inflammatory indices in bronchiectasis . Large-scale
T26	o 1400 1407	effects
T27	o 1442 1465	inflammatory components
T28	o 1469 1485	bronchiectasis .